A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma
Clinical trial NCT06326502 · RECRUITING
Trial details
- NCT number
- NCT06326502
- Sponsor
- Etnova Therapeutics Corp.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-07
- Primary completion
- 2027-03-07
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.